AMRX vs VTRS Stock Comparison

Amneal Pharmaceuticals and Viatris Prices as of Nov 13, 2026 Peers: Industry group
VTRS Viatris Inc
$20.82 +19.4% 1M +90.8% 1Y
Market cap
$23.87B
P/E
–
Revenue (TTM)
$14.73B
Div. yield
–
Generic Drugs Healthcare
5 wins

Head to Head

10 decided of 12

Viatris leads on 5 of the 12 questions below (Viatris 5, Amneal Pharmaceuticals 5). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionAMRXVTRSLeader
Larger companyMarket capitalisation $7.17B $23.87B VTRS
Cheaper on earningsLower P/E, profitable companies only 53.8x -39.3x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS 21.4x 7.8x VTRS
Faster revenue growthRevenue growth, trailing twelve months +8.9% +4.3% AMRX
More profitableNet margin, trailing twelve months 4.2% -4.1% AMRX
Better return on capitalReturn on invested capital 14.3% 0.0% AMRX
Less leveragedLower net debt / EBITDA 4.3x 4.1x VTRS
Higher dividend yieldTrailing dividend yield 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +85.6% +90.8% VTRS
Better 5-year returnAnnualised price return, 5 years +32.7%/yr +8.1%/yr AMRX
Less volatileAnnualised volatility, 1 year 34.3% 30.9% VTRS
Higher overall scoreMean of the five percentile scores vs peers 69/100 66/100 AMRX

Percentile Scorecard

AMRXVTRS

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisAMRXVTRS
Valuation 90 #69 of 660 92 #51 of 660
Growth 70 #189 of 619 51 #303 of 619
Profitability 87 #80 of 595 83 #105 of 595
Financial Health 11 #606 of 683 24 #520 of 683
Shareholder Returns 89 #53 of 459 81 #86 of 459
Overall 69 66
  • AMRX ranked among 695 companies in Pharmaceuticals and Biotechnology
  • VTRS ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodAMRXVTRSSPY
1 month +13.1%+19.4% -2.0%
3 months +17.8%+28.3% -2.8%
6 months +79.2%+26.3% +2.0%
Year to date +69.7%+67.2% +10.6%
1 year +85.6%+90.8% +12.2%
3 years +367.8%+125.8% +68.1%
3 years, per year +67.3%+31.2% +18.9%
5 years +310.4%+47.6% +61.4%
5 years, per year +32.7%+8.1% +10.1%
10 years —-45.1% +248.5%
10 years, per year —-5.8% +13.3%

Risk

MeasureAMRXVTRSSPY
Volatility, 1Y 34.3%30.9% 13.6%
Downside volatility, 1Y 30.7%28.6% 13.9%
Beta vs S&P 500, 1Y 0.670.65 1.00
Return / volatility, 1Y 2.492.94 0.90
Max drawdown, 5Y -75.4%-52.9% -25.4%
From 52-week high -1.5%-1.1% -3.2%
52-week high $21.71$21.06 $779.14
52-week low $11.52$10.19 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleAMRXVTRS
P/E now vs peer median 53.8xmedian 17.0x -39.3xmedian 17.0x
P/S now vs peer median 2.3xmedian 8.4x 1.6xmedian 8.4x
EV/EBITDA now vs peer median 15.1xmedian 14.6x 12.6xmedian 14.6x
P/FCF now vs peer median 193.9xmedian 19.0x 11.3xmedian 19.0x
P/B now vs peer median 14.0xmedian 2.0x 1.7xmedian 2.0x
PEG now vs peer median 0.65median 0.43 1.19median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsAMRXVTRS
Revenue $3.20B $14.73B
Gross profit $1.29B $5.20B
Operating income $478.99M -$4.60M
Net income $175.49M -$607.80M
Free cash flow $38.42M $2.11B
R&D $180.59M $1.00B
EPS (diluted) $0.40 $-0.53
Cash & equivalents $157.40M $1.79B
Total debt $3.12B $13.32B
Shares (diluted) 335.73M 1.15B
Enterprise value $6.41B $17.04B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricAMRXVTRS
P/E 53.8x -39.3x
P/FCF 193.9x 11.3x
P/Operating cash flow 41.2x 9.6x
P/S 2.3x 1.6x
P/B 14.0x 1.7x
P/Tangible book -7.3x 39.4x
EV/EBITDA 15.1x 12.6x
EV/EBIT 21.7x -7,679x
EV/Revenue 3.3x 2.4x
EV/FCF 271.0x 16.7x
EV/Operating cash flow 57.6x 14.2x
PEG (3Y EPS CAGR) 0.65 1.19

Growth

14 metrics
MetricAMRXVTRS
Revenue growth (1Y) 8.9% 4.3%
Revenue CAGR (3Y) 10.2% -1.6%
Gross profit growth (1Y) 19.2% 2.3%
Gross profit CAGR (3Y) 15.0% -5.3%
Operating income growth (1Y) 33.8% 99.8%
Operating income CAGR (3Y) 28.4% -26.1%
Net income growth (1Y) 271.2% 83.5%
Net income CAGR (3Y) 53.6% -32.6%
EPS growth (1Y) 2,085% 83.3%
EPS CAGR (3Y) 83.1% -32.9%
Operating cash flow growth (1Y) -44.9% 25.3%
Operating cash flow CAGR (3Y) -1.1% -0.5%
Free cash flow growth (1Y) -84.6% 27.1%
Free cash flow CAGR (3Y) -35.0% -0.7%

Profitability

14 metrics
MetricAMRXVTRS
Gross margin 40.2% 35.3%
EBITDA margin 21.5% 19.1%
Operating margin 15.0% 0.0%
Pretax margin 6.9% -3.6%
Net margin 4.2% -4.1%
FCF margin 1.2% 14.3%
Operating cash flow margin 5.7% 16.9%
Return on equity 74.3% -4.3%
Return on assets 4.6% -1.7%
Return on invested capital 14.3% 0.0%
Return on capital employed 14.1% 0.0%
Asset turnover 0.7x 0.4x
Cash conversion (OCF / net income) 1.0x -4.1x
Stock comp / revenue 1.2% 1.2%

Financial Health

11 metrics
MetricAMRXVTRS
Debt / assets 59.2% 38.4%
Debt / equity 5.9x 1.0x
Net debt / EBITDA 4.3x 4.1x
Debt / FCF 81.2x 6.3x
Liabilities / assets 89.9% 60.5%
Equity / assets 10.1% 39.5%
Interest coverage – 0.0x
Current ratio 1.9x 1.6x
Quick ratio 1.1x 0.8x
Cash ratio 0.1x 0.3x
Altman Z-score 1.96 1.21

Shareholder Returns

7 metrics
MetricAMRXVTRS
Dividend yield – 2.3%
Net buyback yield 0.0% 1.6%
Shareholder yield 0.0% 3.9%
Payout ratio (earnings) – –
Payout ratio (FCF) – –
Dividend growth (1Y) – –
Dividend CAGR (3Y) – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusAMRXVTRS
Forward P/E 21.4xFY2026 7.8xFY2026
EPS, next fiscal year $1.00FY2026 $2.66FY2026
EPS growth, next FY +20.5%FY2026 +13.2%FY2026
EPS growth, the year after +26.0% -1.9%
Revenue, next fiscal year $3.30BFY2026 $15.33BFY2026
Revenue growth, next FY +9.1%FY2026 +7.2%FY2026
Revenue growth, the year after +12.6% -4.2%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersAMRXVTRS
Held by institutions 51.0% 89.9%
Institutions holding 310 1,033
Change in shares held, QoQ +1.3% +5.6%
Institutions buying 182 491
Institutions selling 86 318
Buyers to sellers 2.12 1.54

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

AMRXVTRS
AMRX 1.00 0.46
VTRS 0.46 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, AMRX and VTRS?

Viatris (VTRS) is the largest by market capitalisation: Amneal Pharmaceuticals (AMRX) $7.17B, Viatris (VTRS) $23.87B.

Which company is growing faster?

Amneal Pharmaceuticals (AMRX) grew revenue fastest over the trailing twelve months: Amneal Pharmaceuticals (AMRX) +8.9%, Viatris (VTRS) +4.3%.

Which company is more profitable?

Amneal Pharmaceuticals (AMRX) has the highest net margin (Amneal Pharmaceuticals (AMRX) 4.2%, Viatris (VTRS) -4.1%). On return on invested capital, Amneal Pharmaceuticals (AMRX) leads (Amneal Pharmaceuticals (AMRX) 14.3%, Viatris (VTRS) 0.0%).

Which stock has performed better?

Over the past year Viatris (VTRS) returned the most: Amneal Pharmaceuticals (AMRX) +85.6%, Viatris (VTRS) +90.8%. Over five years, Amneal Pharmaceuticals (AMRX) compounded fastest (Amneal Pharmaceuticals (AMRX) +32.7%/yr, Viatris (VTRS) +8.1%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Viatris (VTRS) has been the steadiest (Amneal Pharmaceuticals (AMRX) 34.3%, Viatris (VTRS) 30.9%). Volatility measures how widely the price swings, not the risk of the business.

Do AMRX and VTRS move together?

Their daily returns over the past year have a correlation of 0.46, a moderate positive relationship. Holding both diversifies more than two closely linked stocks would.

Which is the better stock, AMRX and VTRS?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Viatris (VTRS) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.